Net Income (Loss) Attributable to Parent in USD of Spero Therapeutics, Inc. from 2015 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Spero Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2015 to Q3 2025.
  • Spero Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$7.38M, a 56.9% increase year-over-year.
  • Spero Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$43.8M, a 1343% decline year-over-year.
  • Spero Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$68.6M, a 401% decline from 2023.
  • Spero Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was $22.8M.
  • Spero Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$89.8M, a 14.7% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

Spero Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$43.8M -$7.38M +$9.77M +56.9% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-13
Q2 2025 -$53.6M -$1.7M +$16.2M +90.5% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-12
Q1 2025 -$69.8M -$13.9M -$1.2M -9.45% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-13
Q4 2024 -$68.6M -$20.9M -$72.1M -141% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-27
Q3 2024 $3.53M -$17.1M -$13.9M -436% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-13
Q2 2024 $17.5M -$17.9M -$5.96M -50.1% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-12
Q1 2024 $23.4M -$12.7M +$631K +4.74% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-13
Q4 2023 $22.8M $51.2M Oct 1, 2023 Dec 31, 2023 10-K 2025-03-27
Q3 2023 -$3.2M +$8.5M +72.7% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$11.9M +$16.8M +58.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 -$13.3M +$19.5M +59.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q3 2022 -$103M -$11.7M +$10.8M +48% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$113M -$28.7M -$10.1M -54.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$103M -$32.8M -$13.4M -69.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$89.8M -$29.3M -$10.7M -57.5% Oct 1, 2021 Dec 31, 2021 10-K 2022-03-31
Q3 2021 -$79.1M -$22.5M -$3.6M -19% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$75.5M -$18.6M -$1.1M -6.29% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 -$74.4M -$19.4M +$3.9M +16.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$78.3M -$18.6M +$6.3M +25.3% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$84.6M -$18.9M -$1.2M -6.78% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$83.4M -$17.5M -$4.3M -32.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$79.1M -$23.3M -$18.2M -357% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$60.9M -$24.9M -$14.3M -134% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-11
Q3 2019 -$46.6M -$17.7M -$7.24M -69.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$39.4M -$13.2M -$3.24M -32.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$36.2M -$5.1M +$5.54M +52.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 -$41.7M -$10.6M +$3.23M +23.3% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-16
Q3 2018 -$44.9M -$10.5M -$627K -6.38% Jul 1, 2018 Sep 30, 2018 10-Q 2018-11-08
Q2 2018 -$44.3M -$9.96M -$787K -8.58% Apr 1, 2018 Jun 30, 2018 10-Q 2018-08-09
Q1 2018 -$43.5M -$10.6M -$4.77M -81.1% Jan 1, 2018 Mar 31, 2018 10-Q 2018-05-10
Q4 2017 -$38.7M -$13.9M -$6.65M -92.2% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-14
Q3 2017 -$32.1M -$9.84M -$3.52M -55.7% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-14
Q2 2017 -$28.6M -$9.17M -$3.11M -51.3% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-14
Q1 2017 -$25.5M -$5.88M +$29K +0.49% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-14
Q4 2016 -$25.5M -$7.21M Oct 1, 2016 Dec 31, 2016 10-K 2018-04-02
Q3 2016 -$6.32M Jul 1, 2016 Sep 30, 2016 10-K 2018-04-02
Q2 2016 -$6.06M Apr 1, 2016 Jun 30, 2016 10-K 2018-04-02
Q1 2016 -$5.91M Jan 1, 2016 Mar 31, 2016 10-K 2018-04-02

Spero Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$68.6M -$91.4M -401% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-27
2023 $22.8M Jan 1, 2023 Dec 31, 2023 10-K 2025-03-27
2021 -$89.8M -$11.5M -14.7% Jan 1, 2021 Dec 31, 2021 10-K 2022-03-31
2020 -$78.3M -$17.4M -28.6% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
2019 -$60.9M -$19.2M -46% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-11
2018 -$41.7M -$2.96M -7.63% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-16
2017 -$38.7M -$13.3M -52% Jan 1, 2017 Dec 31, 2017 10-K 2019-03-14
2016 -$25.5M -$15.3M -150% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-14
2015 -$10.2M Jan 1, 2015 Dec 31, 2015 10-Q 2018-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.